MX9702181A - Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina. - Google Patents

Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.

Info

Publication number
MX9702181A
MX9702181A MX9702181A MX9702181A MX9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A
Authority
MX
Mexico
Prior art keywords
xanthine derivative
rapamycin
combination preparation
containing cyclosporin
xanthine
Prior art date
Application number
MX9702181A
Other languages
English (en)
Other versions
MXPA97002181A (es
Inventor
Martin Schonharting
Ulrich Gebert
Mark Waer
Original Assignee
Hoechst Ag
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Univ Leuven Kath filed Critical Hoechst Ag
Publication of MXPA97002181A publication Critical patent/MXPA97002181A/es
Publication of MX9702181A publication Critical patent/MX9702181A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Preparaciones de combinacion que contienen ciclosporina A y un derivado de kantina o bien FX506 y un derivado de kantina o rapamicina y un derivado de kantina son adecuados para su uso en transplante de organos como por ejemplo lupus eritematoso sistématico, artritis reumatoide, psoriasis, pénfigo, dermatitis atopica, miositis, esclerosis multiple, síndrome nefrotico (especialmente glomerulonefritis), colitis ulcerativa o bien diabetes juvenil.
MX9702181A 1994-08-25 1995-08-07 Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina. MX9702181A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4430127.9 1994-08-25
DE4430127A DE4430127A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
PCT/EP1995/003126 WO1996005854A2 (en) 1994-08-25 1995-08-07 Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative

Publications (2)

Publication Number Publication Date
MXPA97002181A MXPA97002181A (es) 1997-06-01
MX9702181A true MX9702181A (es) 1997-06-28

Family

ID=6526514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702181A MX9702181A (es) 1994-08-25 1995-08-07 Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.

Country Status (9)

Country Link
US (2) US6046328A (es)
EP (1) EP0797448B1 (es)
CN (1) CN1096859C (es)
AT (1) ATE233095T1 (es)
AU (1) AU714129B2 (es)
CA (1) CA2199949A1 (es)
DE (2) DE4430127A1 (es)
MX (1) MX9702181A (es)
WO (1) WO1996005854A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100494182C (zh) 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
US20070105878A1 (en) * 2005-10-03 2007-05-10 Andrew Reaume Purine formulations and methods for managing disorders
EP1787645A1 (en) * 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US8481023B2 (en) * 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CA2683407C (en) * 2007-04-04 2016-09-20 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2009108383A2 (en) * 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
WO2015073691A1 (en) * 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
WO2022042390A1 (zh) * 2020-08-25 2022-03-03 广东众生睿创生物科技有限公司 羟基嘌呤类化合物用于治疗皮肤疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007566A2 (en) * 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
DK0584347T3 (da) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser

Also Published As

Publication number Publication date
CN1162919A (zh) 1997-10-22
CA2199949A1 (en) 1996-02-29
CN1096859C (zh) 2002-12-25
WO1996005854A3 (en) 1996-04-11
AU714129B2 (en) 1999-12-16
ATE233095T1 (de) 2003-03-15
WO1996005854A2 (en) 1996-02-29
AU3342895A (en) 1996-03-14
DE69529769D1 (de) 2003-04-03
EP0797448B1 (en) 2003-02-26
US6432968B1 (en) 2002-08-13
EP0797448A2 (en) 1997-10-01
US6046328A (en) 2000-04-04
DE4430127A1 (de) 1996-03-14

Similar Documents

Publication Publication Date Title
MX9702181A (es) Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.
EP0713490A1 (en) C-22 ring stabilized rapamycin derivatives
MY134806A (en) Cyclosporins
WO2001042246A3 (en) PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
AU7211691A (en) Novel vehicle gases and their use in medical preparations
WO1997003654A3 (en) Pharmaceutical compositions
AU6019594A (en) Text input transliteration system
AU6018694A (en) Text transliteration system
EP1707641A3 (en) Evolution of whole cells and organisms by recursive sequence recombination
MY109822A (en) (s)-(+)-hydroxychloroquine
WO2001027118A3 (de) Bicyclische imidazo-5-yl-aminderivate
AU1319895A (en) Cyclodextrin derivatives for solubilising hydrophobic chemical compounds such as drugs, and methods for preparing same
GR3037059T3 (en) Desosamino derivatives of macrolides as immunosuppressants and antifungal agents.
WO1994026263A3 (en) Use of a transition metal complex for the treatment of septic shock
AU4823993A (en) Polypeptides involved in streptogramin biosynthesis, nucleotide sequences coding for said polypeptides and use thereof
AU4995793A (en) Biological applications of alkaloids derived from the tunicate eudistoma sp.
AU6243696A (en) Gene preparations
EP0715519A4 (en) IMMUNOMODULATIVE, ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE COMPOUNDS: 5,6-DIDEOXY, 5-AMINO DERIVATIVES OF IDOSE AND 6-DEOXY, 6-AMINO DERIVATIVES OF GLUCOSE
IL109991A0 (en) Genes encoding branched-chain alpha-ketoacid dehydrogenase complex from streptomyces avermitilis
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
IL81508A (en) Phytopathogenic antibiotic compositions comprising rifamycin derivatives
AU1554792A (en) Nucleotide probes and primers for genetic analysis
EP0828258A3 (en) Dielectric fluids
AU6386894A (en) Arrangement of chair, bench, or the like, with pivotable back rest and associated neck support
EP0891727A3 (en) Compressed-air column, cushioned and turning, particularly suitable for office chairs